Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydralazine dose-response curve analysis.

D A Graves1, K T Muir, W Richards

  • 1Fisons Pharmaceuticals, Rochester, New York 14623.

Journal of Pharmacokinetics and Biopharmaceutics
|August 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HKD-MGIN: a physics informed graph neural network using heat kernel diffusion for mapping adolescent functional brain connectivity.

Machine learning for computational science and engineering·2026
Same author

Corrigendum to "Healthcare-worker-associated outbreak of Panton-Valentine-leukocidin-producing meticillin-sensitive Staphylococcus aureus in a large neonatal unit in London: successful targeted suppression therapy following failure of mass suppression therapy" [J Hosp Infect 122 (2022) 148-156].

The Journal of hospital infection·2025
Same author

Grading systems for tracheal intubation using videolaryngoscopy.

BJA education·2025
Same author

NHS tie-in impact on dental profession.

British dental journal·2025
Same author

Implementing Transitional Care Interventions for Surgical Patients: A Scoping Review.

Journal of advanced nursing·2025
Same author

Does A Dietitian-Led Celiac Disease Clinic (DLCC) Facilitate Timely Diagnosis and Nutrition Care for Patients With Celiac Disease?

Journal of gastroenterology and hepatology·2025
Same journal

Integrated equation to evaluate accumulation profiles of drugs eliminated by Michaelis-Menten kinetics.

Journal of pharmacokinetics and biopharmaceutics·2010
Same journal

Applications of a recirculatory stochastic pharmacokinetic model: limitations of compartmental models.

Journal of pharmacokinetics and biopharmaceutics·2010
Same journal

Effect of plasma protein and tissue binding on the time course of drug concentration in plasma.

Journal of pharmacokinetics and biopharmaceutics·2010
Same journal

Pharmacokinetics of methotrexate in solid tumors.

Journal of pharmacokinetics and biopharmaceutics·2010
Same journal

Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.

Journal of pharmacokinetics and biopharmaceutics·2010
Same journal

Comparison of the in vitro and in vivo release of digoxin from four different soft gelatin capsule formulations.

Journal of pharmacokinetics and biopharmaceutics·2010
See all related articles

This study found that hydralazine

Area of Science:

  • Pharmacology and Hypertension Research
  • Clinical Trial Design and Analysis

Background:

  • Hypertension management often requires combination therapy.
  • Understanding hydralazine's dose-response is crucial for optimizing treatment.

Purpose of the Study:

  • To compare the safety and antihypertensive efficacy of immediate-release (IR) and extended-release (ER) hydralazine.
  • To analyze hydralazine's dose-response relationship using nonlinear mixed-effects modeling.

Main Methods:

  • A multicenter, double-blind, randomized study involving 181 patients.
  • Patients received diuretic therapy, randomized to IR or ER hydralazine regimens at varying doses.
  • Nonlinear mixed-effects modeling (NONMEM) analyzed sitting diastolic blood pressure (BP).

Related Experiment Videos

Main Results:

  • All tested factors, including body weight, time, beta-blocker therapy, and acetylator class, significantly impacted BP (p < 0.05).
  • The maximum antihypertensive response (Emax) was 9.4 mm Hg.
  • The dose eliciting 50% of maximum response (D50) varied by acetylator status (0.87 mg/kg for slow, 1.68 mg/kg for fast).

Conclusions:

  • Hydralazine's antihypertensive effect is influenced by patient factors like acetylator status and weight, not the release formulation.
  • Concomitant beta-blocker therapy significantly enhanced hydralazine's BP-lowering effect.
  • NONMEM provided valuable insights into hydralazine's pharmacodynamics beyond traditional analysis.